Venous Thrombogenesis and Cervical Cancer: Plasma MicroRNAs as Prognostic Indicators of Tumor Behavior

Cervical cancer (CC) is the fourth most common cancer among women globally, with venous thromboembolism (VTE) representing a life-threatening complication. Cancer-associated thrombosis (CAT) arises from tumor-driven activation of hemostasis, worsening prognosis. Recently, circulating microRNAs (miRNAs) have emerged as potential biomarkers for both CAT and cervical tumorigenesis. Thus, this study aimed to assess the implications of five miRNAs-miR-20a-5p, -23a-3p, -125b-5p, -145-5p, and -616-3p-in CC-related VTE context. These miRNAs were quantified by RT-qPCR in plasma from 69 CC patients before treatment. Briefly, VTE occurred in nine patients, decreasing overall survival (OS) [log-rank test, <i>p</i> = 0.005; hazard ratio (HR) = 4.78; 95% confidence interval (CI), 1.42-16.05]. Lower miR-20a-5p levels predicted VTE (ꭓ² test, <i>p</i> = 0.027) and, in subgroup analyses, they were linked to cervical squamous cell carcinoma (CSCC) and older age (ꭓ² test, <i>p</i> = 0.003 and <i>p</i> = 0.043, respectively). In VTE patients, miR-145-5p downregulation was associated with improved OS (log-rank test, <i>p</i> = 0.018), an effect also observed in the adenocarcinoma (ADC) subgroup (log-rank test, <i>p</i> = 0.039). The remaining miRNAs showed subtype-specific links to clinicopathological features and survival. These findings highlight the potential value of circulating miRNAs in thrombotic risk and prognosis assessment in CC.